SiSaf Ltd.

The positive Phase III results and subsequent US approval of lecanemab for Alzheimer’s disease was reflected by a spike in enthusiasm for the central nervous system (CNS) space among the 90 or so resp

For the third installment of our Scrip Asks…What Does 2023 Hold For Biopharma? series, we asked industry leaders and experts how the sector would be affected by the global headwinds of political ins